Product Images Memantine Hydrochloride And Donepezil Hydrochloride
View Photos of Packaging, Labels & Appearance
- Principal Display Panel – 14/10 mg bottle - label 14mg
- Principal Display Panel – 28/10 mg bottle - label 28mg
- Memantine Hydrochloride Structural Formula - memantine and donepezil hydrochlorides 1
- Figure 8 - memantine and donepezil hydrochlorides 10
- Donepezil Hydrochloride Structural Formula - memantine and donepezil hydrochlorides 2
- Figure 1 - memantine and donepezil hydrochlorides 3
- Figure 2 - memantine and donepezil hydrochlorides 4
- Figure 3 - memantine and donepezil hydrochlorides 5
- Figure 4 - memantine and donepezil hydrochlorides 6
- Figure 5 - memantine and donepezil hydrochlorides 7
- Figure 6 - memantine and donepezil hydrochlorides 8
- Figure 7 - memantine and donepezil hydrochlorides 9
Product Label Images
The following 12 images provide visual information about the product associated with Memantine Hydrochloride And Donepezil Hydrochloride NDC 69680-185 by Vitruvias Therapeutics, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Principal Display Panel – 14/10 mg bottle - label 14mg
This is a medication label for a capsule containing 14 mg of memantine HCl extended release and 10 mg of donepezil HCl. The usual dosage is one capsule per day. The medication should be stored at 20°C to 25°C and dispensed in a light-resistant container. It is manufactured by Xiamen LP Pharmaceutical Co., Ltd. in China and distributed by Vitruvias Therapeutics in the USA. The packaging includes information like lot number, expiration date, and package insert details.*
Principal Display Panel – 28/10 mg bottle - label 28mg
Memantine Hydrochloride Structural Formula - memantine and donepezil hydrochlorides 1
Figure 8 - memantine and donepezil hydrochlorides 10
Donepezil Hydrochloride Structural Formula - memantine and donepezil hydrochlorides 2
Figure 1 - memantine and donepezil hydrochlorides 3
Figure 2 - memantine and donepezil hydrochlorides 4
Figure 3 - memantine and donepezil hydrochlorides 5
Figure 4 - memantine and donepezil hydrochlorides 6
Figure 5 - memantine and donepezil hydrochlorides 7
This text describes a study evaluating the clinical improvement and decline over 3 months of drug treatment with donepezil hydrochloride at a dosage of 10 mg/day compared to placebo. The results display certain percentage improvements and declines over the specified time frame.*
Figure 6 - memantine and donepezil hydrochlorides 8
Figure 7 - memantine and donepezil hydrochlorides 9
This text presents a chart showing the change in ADCS-ADL scores from baseline to 6 months for patients taking donepezil hydrochloride 10 mg/day compared to those on a placebo. The chart illustrates the mean values and standard errors for each group at 0, 3, and 6 months of drug treatment. The chart visually depicts the clinical improvement or decline in ADCS-ADL scores over the course of the study.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
